Shares of Park Ha Biological Technology (BYAH) jumped 7.1% to $2.55 on September 14 after the Wuxi, China-based skincare company disclosed a $2.97 million private placement that closed three days earlier — raising fresh questions about whether repeated stock sales are a lifeline or a slow bleed for shareholders.
Three Capital Raises in Nine Months Spell a Pattern
The latest deal issued 1,080,000 Class A shares at $2.75 apiece plus warrants covering another 1,845,452 shares, raising roughly $2.97 million before expenses. This follows a $2.0 million registered offering in June at just $1.50 per share and a $2.45 million public offering in January at $0.112 per unit. Together, that's roughly $7.4 million raised in 2026 alone — meaningful for a firm whose full-year 2025 revenue was only $2.52 million. The company keeps tapping equity markets to cover basic operations rather than generating enough cash internally.
The Warrants Create a Dilution Overhang
The warrants are exercisable immediately, carry a five-year term, and have a strike price of just $1.10 per share — well below today's price. If fully exercised, total new shares from this deal alone would reach 2.93 million, adding to a share count that already ballooned 111% in the past year. Each wave of dilution (more shares splitting the same pie) chips away at existing holders' ownership stake.
A $24 Million Loss and a Pending Lawsuit Loom Large
Park Ha posted a $24.4 million net loss on just $2.52 million in revenue for fiscal 2025. Meanwhile, a securities class action alleges the company structured its IPO with a public float of just 1,200,000 shares — under 5% of total shares — enabling what the suit calls coordinated price manipulation before a 93% single-day crash in July 2025 that erased over $1 billion in market cap.
The lead plaintiff deadline is September 28, 2026.
The Bull Case Is Razor-Thin The stock's pop likely reflects the $2.75 PIPE price sitting above today's trading range, signaling at least some investor willingness to buy at a premium. Park Ha also recently won approval for an Amazon North America storefront , a potential channel into U.S. consumers. But net proceeds are earmarked only for "general working capital," not a specific growth initiative. For a company burning cash at multiples of its revenue, each new share sale buys time — not a turnaround.